Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NanoViricides Inc
NNVC | US
1.04
USD0
0%
NNVC | US
Loading StockChartView...
About NanoViricides Inc
Sector
Healthcare
Industry
Drug Manufacturers - Major
Earnings date
30/06/2024
As of date
14/04/2026
Close
1.04
Open
1.05
High
1.06
Low
1.02
NanoViricides Inc. a nano-biopharmaceutical research and development company discovers develops and commercializes drugs for the treatment of viral infections. The company develops Monkeypox Treatment for Monkeypox virus; Adenovirus 71 Treatment for severe pediatric hepatitis caused by Adenovirus 71 or related viruses; and HerpeCide Program Expansion Drug project that develops broad-spectrum nanoviricide drugs against different herpes viruses for different indications. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide an escape-resistant anti-HIV nanoviricide. In addition it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. The company was founded in 2005 and is based in Shelton Connecticut.
View LessNNVC | US
Risk
73.9
Sharpe
-0.10
Luna's Score
37/100
Recommendation
Sell
Luna says (NNVC | US)
What's Working
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
82.0%1 month
73.9%3 months
76.1%6 months
90.8%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.91
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-1.11
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-7.76M
MarketCap
15.26M
MarketCap(USD)
15.26M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-63.00
Short ratio
3.01
Short perc.
3.20
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.24
Range1M
0.35
Range3M
0.42
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.32
Price X volume
58.19K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.11 | 21.06 | Cheaper |
| Ent. to Revenue | - | 5.64 | - |
| PE Ratio | - | 41.17 | - |
| Price to Book | 1.91 | 11.46 | Cheaper |
| Dividend Yield | - | 3.27 | - |
| Std. Deviation (3M) | 76.11 | 39.12 | Riskier |
| Debt to Equity | - | 1.72 | - |
| Debt to Assets | - | 0.31 | - |
| Market Cap | 15.26M | 200.67B | Emerging |
